June 13, 2025- Thermo Fisher Scientific announced that the Regeneron Genetics Center® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease.
The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC’s established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC’s selection of Olink Explore HT follows the platform’s selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world’s largest human proteomics study.
The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC’s world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples.